Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].

Zhonghua zhong liu za zhi [Chinese journal of oncology] - 23 Feb 2017

Pi C, Zhang Y C, Xu C R, Zhou Q

Abstract excerpt

Recently, with the research progress in molecular classification, the treatment of advanced non-small cell lung cancer (NSCLC) has been established as a model of anti-tumor treatment of precision medicine. The discovery of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) has transformed the treatment of NSCLC from platinum based doublet chemotherapy into era of target therapy. EGFR-TKI, such...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epithelial-Mesenchymal Transition

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Genes, erbB-1

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 28219202
DOI: 10.3760/cma.j.issn.0253-3766.2017.02.004

Genes

EGFR
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].PMID 28219202Read ↗

[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutation].Semantic proximity Read ↗

[Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation].Semantic proximity Read ↗

The resistance mechanisms and treatment strategies for <i>EGFR</i>-mutant advanced non-small-cell lung cancerSemantic proximity Read ↗

[Research progress of the resistance mechanism of non-small cell lung cancer to EGFR-TKIs].Semantic proximity Read ↗

[The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant non-small cell lung cancer].Semantic proximity Read ↗

Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.Semantic proximity Read ↗

Emerging treatment for advanced lung cancer with EGFR mutation.Semantic proximity Read ↗

[Application strategies of the third-generation EGFR-TKI in the context of precision medicine].Semantic proximity Read ↗

Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.Semantic proximity Read ↗

[Advances in research on primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients].Semantic proximity Read ↗

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.Semantic proximity Read ↗

Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.